Clinical trials
Participation clinical trials
Below are recruiting participation clinical trials, each written for real people, not researchers. We’re tracking 2,217 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06120283RecruitingPhase 1
Testing a new drug for breast cancer and other solid tumors
This trial tests a new oral drug (BGB-43395) alone or with other treatments for people with advanced breast cancer or other solid tumors that depend on CDK4. It aims to find safe doses and see if the drug helps shrink tumors or slow growth.
Denver, ColoradoAges 18 years+ - NCT07444567RecruitingPhase 3
Continuing benralizumab treatment after a previous study
This trial lets people who completed an earlier benralizumab study and are benefiting from the medicine keep receiving it. The goal is to provide ongoing access while we continue to monitor safety and effectiveness.
Aurora, ColoradoAges 6 years+ - NCT07378644RecruitingPhase 2/Phase 3
Testing SKY-0515 for Huntington's disease
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
Englewood, ColoradoAges 25 years+ - NCT07431177RecruitingPhase 2
Study of an investigational drug for non-segmental vitiligo
This study tests an investigational drug (GIA632) in people with non-segmental vitiligo. It aims to see if different doses can safely and effectively restore color to white patches.
Birmingham, AlabamaAges 18–99 - NCT07493304RecruitingPhase 3
Preventing blood clots in people with cancer
This trial tests a new anticoagulant medication to treat and prevent blood clots in patients with active cancer. You may qualify if you have a recent clot in your leg or lungs and are already taking a blood thinner.
Hialeah, FloridaAges 18 years+ - NCT07218627RecruitingPhase 1
Study of an investigational medicine for heart failure
This study tests an experimental medicine called NNC0537-1482 for people with heart failure. It aims to see if the medicine helps improve symptoms and heart function.
LondonAges 40–75 - NCT07570654RecruitingPhase 2/Phase 3
Testing COMP360 for post-traumatic stress disorder
This study tests whether COMP360, a new treatment, can help people with PTSD feel better and cope with their symptoms. The research team will measure how safe it is and how well it works over time.
New York, New YorkAges 18 years+ - NCT05431088RecruitingPhase 2/Phase 3
Study of osivelotor for sickle cell disease
This study tests an investigational medicine called osivelotor for people with sickle cell disease (SCD). The goal is to see if it can reduce pain crises and improve overall health. It is for adults and adolescents aged 12 and older.
Mobile, AlabamaAges 12 years+ - NCT07545122RecruitingPhase 1
Testing CT-202 for Triple Negative Breast, Colorectal, and Bladder Cancers
This early-stage trial tests a new antibody drug called CT-202 in patients whose cancer has come back after standard treatments. The drug is designed to target cancer cells that have a specific protein called Nectin-4, and may help the immune system fight the cancer.
Gold Coast, QueenslandAges 18 years+ - NCT07727538RecruitingPhase 3
Olezarsen for children with familial chylomicronemia syndrome
This trial tests a drug called olezarsen in children with a genetic condition that causes extremely high triglycerides. It aims to lower triglyceride levels and prevent pancreatitis.
Birmingham, AlabamaAges 2–17 - NCT06764316RecruitingPhase 1
Safety study of BAY 3547926 for advanced liver cancer
This trial tests a new drug called BAY 3547926 for people with advanced liver cancer that cannot be removed with surgery or has not responded to other treatments. The goal is to see if the drug is safe and how well it works.
Dothan, AlabamaAges 18 years+ - NCT07665437RecruitingPhase 3
Long-term safety study of remibrutinib for hidradenitis suppurativa
This study tests the long-term safety and effectiveness of remibrutinib for people with moderate to severe hidradenitis suppurativa (HS) who have already completed a 68-week treatment period in a related study.
Fort Smith, ArkansasAges 18–100 - NCT07621809RecruitingPhase 3
Ianalumab versus placebo for Sjögren's disease with high symptom burden
This study tests whether a new drug called ianalumab can reduce dry mouth and other symptoms in people with Sjögren's disease—a condition where the immune system attacks moisture-producing glands. Participants will receive either ianalumab or a placebo (inactive injection) over 52 weeks to see if the drug helps.
Peoria, ArizonaAges 18 years+ - NCT07088926RecruitingPhase 2
Study of a new medicine for bronchiectasis with chronic Pseudomonas infection
This study tests a new medicine (AZD0292) given through a vein for people with bronchiectasis and a chronic Pseudomonas lung infection. It aims to see if it can reduce flare-ups and improve lung health.
Orange, CaliforniaAges 12 years+ - NCT07226986RecruitingPhase 1/Phase 2
Study of AMO959 with Lutetium-177 and ARPI for prostate cancer
This trial tests a new combination therapy for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. It combines an experimental drug (AMO959) with a targeted radiation treatment (Lutetium-177) and a standard hormone therapy to see if it helps control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT06481306RecruitingPhase 1/Phase 2
Testing a new drug for sickle cell disease in healthy people and patients
This early-phase study tests a new drug (BMS-986470) for people with sickle cell disease who have frequent pain crises. The goal is to see if it can safely reduce crises. It includes a small group of healthy volunteers as well.
Birmingham, AlabamaAges 18 years+ - NCT07710768RecruitingPhase 1
A study on how UBT251 affects certain drugs in people with extra weight
This study tests if a new medicine called UBT251 changes how the body processes caffeine, midazolam (a sedative), and warfarin (a blood thinner). It is for generally healthy adults with a Body Mass Index (BMI) between 27 and 40.
Cypress, CaliforniaAges 18–65 - NCT07146100Recruiting
Long-term follow-up after AHB-137 treatment for hepatitis B
This study follows participants with chronic hepatitis B who previously responded to the drug AHB-137. The goal is to track long-term health and safety after their treatment.
Hefei, AnhuiAges 18 years+ - NCT07217171RecruitingPhase 1
Study of EVOLVE104 for advanced bladder and squamous cell cancers
This trial tests an experimental drug called EVOLVE104 for people with advanced bladder cancer or certain types of squamous cell cancers. It aims to see if the drug is safe and if it can help shrink tumors.
Duarte, CaliforniaAges 18 years+ - NCT04772079RecruitingPhase 3
Test drug safety and effectiveness for youth plaque psoriasis
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
Ciudad Autonoma de Buenos Aires, Buenos AiresAges 4–18 - NCT06618287RecruitingPhase 1/Phase 2
Testing BMS-986507 for advanced lung and breast cancers
This study tests a new drug called BMS-986507, given in different combinations, for people with advanced solid tumors (lung cancer or breast cancer that has spread). It looks at safety, how the drug works in the body, and if it helps shrink tumors.
Birmingham, AlabamaAges 18 years+ - NCT07325136RecruitingPhase 1/Phase 2
BMS-986525 for Relapsed Small Cell Lung Cancer
This study tests a new drug called BMS-986525, alone or with other treatments, for people with small cell lung cancer that has come back or not responded to treatment. It aims to find out if the drug is safe and tolerable.
Detroit, MichiganAges 18 years+ - NCT07468071RecruitingPhase 1/Phase 2
Continuing opnurasib treatment for patients who are benefiting
This trial allows people who are already taking opnurasib in another Novartis study and seeing good results to keep receiving it. The goal is to let them continue treatment without interruption.
Sint-Niklaas, Oost VlaanderenAges 18–100 - NCT07486934RecruitingPhase 3
Study of DYNE-101 for Myotonic Dystrophy Type 1
This trial tests an experimental drug called DYNE-101 to see if it can help people with myotonic dystrophy type 1 (DM1). The study aims to improve muscle function and daily life. It is for adults who can walk and stand up from a chair without help.
La Jolla, CaliforniaAges 16 years+
Hear when a new Participation trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for participation?
- Yes. Clin2 currently lists 2,217 recruiting participation studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a participation trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a participation trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.